Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program
- 7 February 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 113 (1), 189-196
- https://doi.org/10.1007/s10549-008-9918-3
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomasBreast Cancer Research, 2007
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based StudyCancer Epidemiology, Biomarkers & Prevention, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancerAnnals Of Oncology, 2005
- Distinct breast cancer incidence and prognostic patterns in the NCI?s SEER program: suggesting a possible link between etiology and outcomeBreast Cancer Research and Treatment, 2005
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987